Product logins

Find logins to all Clarivate products below.


Psoriasis (Moderate to Severe) | Decision Base | US | 2015

With the Entry of New Oral and Biological Agents, Where Are the Remaining Areas of Opportunity in an Increasingly Crowded Market?

Affecting more than three million people in the major pharmaceutical markets, moderate to severe psoriasis represents a large market with substantial commercial opportunity. However, competition is set to intensify with the recent launch of the first approved IL-17 inhibitor, secukinumab (Novartis’s Cosentyx), and other highly efficacious biologics in the late-stage pipeline. These agents’ efficacy on more-stringent measures of response (i.e., PASI 90 and PASI 100 response rates) and superior efficacy to current agents in head-to-head studies will significantly raise the bar for psoriasis therapies.

Related Market Assessment Reports

Report
Major Depressive Disorder (DSM-V) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Major Depressive Disorder (US)
Major depressive disorder (MDD) is a widely drug-treated condition managed with multiple drug classes, most commonly selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine…
Report
Atopic Dermatitis / Atopic Eczema – Geographic Focus: China – Atopic Dermatitis – China In-Depth (China)
China’s atopic dermatitis (AD) market remains grounded in established topical and systemic therapies, although limitations in longterm disease control leave a sizable unmet need among…
Report
Dry and Wet Age-Related Macular Degeneration – Access & Reimbursement – Access & Reimbursement – Age-Related Macular Degeneration (US)
The U.S. wet AMD market is led by intravitreal therapies such as Eylea, Eylea HD, and Vabysmo, alongside the continued off-label use of compounded Avastin, driven by cost considerations. In…
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…